Amundi Increases Stock Position in Illumina, Inc. $ILMN

Key Points

• Amundi increased its Illumina stake by 2.6% in the second quarter, bringing its holdings to 361,203 shares worth approximately $63.5 million. Institutional investors collectively own 89.42% of the company.
• Illumina exceeded quarterly expectations, reporting $1.31 in EPS and $1.16 billion in revenue, with revenue up 9.4% year over year. The company set fiscal 2026 EPS guidance at $5.30–$5.40.
• Analyst sentiment remains mixed, with the stock carrying a consensus “Hold” rating and a $199.12 target price. Meanwhile, insiders sold more than 2 million shares worth approximately $436.6 million over the past three months.

Amundi lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 2.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 361,203 shares of the life sciences company's stock after purchasing an additional 9,204 shares during the quarter. Amundi owned 0.24% of Illumina worth $63,510,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ILMN. California State Teachers Retirement System raised its position in shares of Illumina by 16,869.5% in the second quarter. California State Teachers Retirement System now owns 40,144,099 shares of the life sciences company's stock worth $7,058,537,000 after buying an additional 39,907,533 shares in the last quarter. Capital World Investors grew its position in Illumina by 0.6% during the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company's stock worth $2,636,483,000 after buying an additional 124,323 shares in the last quarter. BlackRock Inc. purchased a new position in Illumina during the second quarter worth about $3,374,423,000. State Street Corp increased its stake in Illumina by 3.2% in the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company's stock worth $811,895,000 after acquiring an additional 190,324 shares during the last quarter. Finally, WCM Investment Management LLC increased its stake in Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock worth $715,579,000 after acquiring an additional 1,851,848 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Stock Down 1.8%

ILMN stock opened at $201.27 on Friday. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $231.81. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The firm has a market cap of $30.39 billion, a PE ratio of 37.55, a price-to-earnings-growth ratio of 2.90 and a beta of 1.46. The business has a 50 day moving average of $200.54 and a 200 day moving average of $161.87.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. Illumina's revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts forecast that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Deutsche Bank Aktiengesellschaft cut shares of Illumina to a "hold" rating in a research note on Wednesday, August 5th. Evercore reiterated an "outperform" rating on shares of Illumina in a research report on Monday, July 6th. Citigroup boosted their price target on shares of Illumina from $95.00 to $113.00 and gave the stock a "sell" rating in a research note on Monday, August 3rd. JPMorgan Chase & Co. upped their price target on shares of Illumina from $220.00 to $230.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. Finally, Canaccord Genuity Group raised their price objective on Illumina from $190.00 to $205.00 and gave the company a "hold" rating in a research note on Monday, August 3rd. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $199.12.

Insiders Place Their Bets

In other Illumina news, SVP Christensen Wedel sold 1,033 shares of the company's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the transaction, the senior vice president owned 14,023 shares in the company, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of the firm's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the sale, the director directly owned 770,350 shares in the company, valued at approximately $168,244,440. The trade was a 13.43% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 2,062,465 shares of company stock valued at $436,589,802. Corporate insiders own 2.90% of the company's stock.

About Illumina

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company's sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.